
Aptar's Dual-Active Material Science Technology Simultaneously Controls Moisture and Oxygen for Pharmaceutical Drugs and Medical Devices
This new solution marks a significant material science breakthrough in the pharmaceutical industry, extending Aptar CSP Technologies' 3-Phase Activ-Polymer™ technology into new use cases where a combination of humidity and oxidation can compromise the efficacy, safety, and shelf life of sensitive oral solid dose drugs, medical devices, implantable mesh devices, microarray patches and transdermal delivery systems.
'This launch reflects years of development, engineering excellence, and a deep understanding of our customers' most pressing stability challenges,' said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. 'There has never been a singular, standalone active material aimed at protecting against both oxidation and moisture-related degradation at this level of precision across multiple platforms. We're proud to offer a solution that is not only scientifically differentiated but can also be commercially validated.'
Aptar's new dual-active technology can be customized for a range of product formats and development stages, from early R&D to commercial launch. Aptar's technology can help support regulatory compliance and product protection across a variety of formats, aimed at helping companies meet strict International Council for Harmonization (ICH) stability requirements while maintaining performance and integrity of sensitive drug or device components.
In addition to protection technology for oral solid dose GLP-1, Aptar also offers a range of high-quality elastomeric components for GLP-1 drug products, including plungers and rigid needle shields. Pharmaceutical companies have validated Aptar's elastomeric components and are partnering with Aptar to develop injectable solutions for GLP-1. By combining digital and Aptar's patient services, Aptar offers fully integrated solutions, which helps drug manufacturers create differentiated drug delivery systems and enhance patient experiences for GLP-1 and other applications.
About Aptar
Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risk the product development process, and provide complete solutions that improve consumers' and patients' lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.csptechnologies.com and www.aptar.com.
This press release contains forward-looking statements, including the potential outcomes of the 3-Phase Activ-Polymer™ technology. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
UBS Lowered its Price Target Berkshire Hathaway (BRK-B), Kept a Buy Rating
Berkshire Hathaway Inc. (NYSE:BRK-B) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 3, analyst Brian Meredith from UBS lowered its price target on Berkshire Hathaway Inc. (NYSE:BRK-B) from $606 to $591, while keeping a Buy rating on the stock. The analyst noted that the price revision reflects the conservative investment approach of Berkshire Hathaway Inc. (NYSE:BRK-B). The company's investment approach prioritizes liquidity and risk mitigation amidst volatile market conditions. However, while the analyst lowered the price target, he maintained a Buy rating due to the company's strong balance sheet and diversified investment portfolio. Brian Meredith noted that these factors are key strengths of Berkshire Hathaway Inc. (NYSE:BRK-B), which supports its long-term value. Skyscrapers with background of graphs and arrows Moreover, Qualivian Investment Partners also mentioned Berkshire Hathaway Inc. (NYSE:BRK-B) in its Q1 2025 investor letter. The fund noted the company to be among the top three contributors for the quarter. Berkshire Hathaway Inc. (NYSE:BRK-B) is a large holding company that owns and operates various businesses through its subsidiaries. While we acknowledge the potential of BRK-B as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Companies Like Pfizer Inc (PFE) are Boosting the Cannabis Light Market
Pfizer Inc. (NYSE:PFE) is one of the . On July 1, GlobalNewswire reported that the Cannabis Light Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% from 2025 to 2030. This is because companies like Pfizer Inc. (NYSE:PFE) have entered the industry. In 2021, Pfizer Inc. (NYSE:PFE) entered the medical cannabis sector by acquiring Arena Pharmaceuticals for $6.7 billion. The report highlighted that the industry is rapidly evolving due to increased legalization and cultivation activities around the globe. This has led to key pharmaceutical companies like Pfizer Inc. (NYSE:PFE) to forge partnerships to maximize the efficient use of cannabis using advanced lighting techniques. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. Pfizer Inc. (NYSE:PFE) is an international biopharmaceutical company that researches, develops, manufactures, and sells medicines and vaccines. Its products cover a wide range of health areas, including oncology, primary care, and specialty care. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Clearwater Analytics Selected by Germany's Largest Public Insurer for Enhanced Investment Operations
Clearwater Analytics Holdings Inc. (NYSE:CWAN) is one of the most promising stocks according to Wall Street analysts. On July 2, Clearwater Analytics announced that Versicherungskammer Group selected Clearwater Analytics' cloud-based platform to enhance its middle, back-office, and risk functions for investment operations. The Versicherungskammer Group is the largest public insurer in Germany active in Bavaria, the Palatinate, Saarland, as well as in Berlin and Brandenburg. The decision to select Clearwater Analytics' cloud-based platform follows an operating model review initiated in 2024 and a subsequent rigorous selection process. A wide shot of a large financial data center. The partnership shifts Versicherungskammer's investment operations strategy and is central to its goal of future-proofing the company's investment capabilities. Additionally, the partnership allows the company to now focus on enhancing data quality, supporting decision-making processes, and improving risk and performance management. Clearwater Analytics Holdings Inc. (NYSE:CWAN) develops and provides a SaaS solution for automated investment data aggregation, reconciliation, accounting, and reporting services internationally. While we acknowledge the potential of CWAN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data